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Summary We report our experience with the technique of lymphatic mapping using patent blue V dye in patients with limb malignant
melanoma. The technique is based on the hypothesis that embolic metastases occur along lymphatic channels to a 'sentinel' lymph node: the
draining lymph node nearest the site of the primary malignant melanoma. Patent blue V dye (0.5-1.0 ml) is injected intradermally around the
site of the melanoma. Immediately the groin or axilla is opened and the blue lymphatic channels followed to the sentinel node. The node is
removed and examined by both haematoxylin and eosin (H&E) and immunohistochemical staining. We have carried out this technique in 35
patients, all ofwhom had 'clinically assessed' stage I disease. In all 35 patients, sentinel nodes were identified, and nine were found to contain
unsuspected micrometastases. Our initial evaluation of intraoperative lymphatic mapping is very promising. The technique is practicable and
easy to master. If 25% of patients with cutaneous malignant melanoma who are clinically stage I have nodal disease, this has great
importance not only for staging and treatment but also for all future therapeutic trials.
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Radical lymph node clearance is generally recommended for
melanoma patients with clinically suspicious nodes or biospy-
proven nodal disease. The role of elective lymphadenectomy in
melanoma patients without clinical evidence of lymph node
metastases remains controversial (Scott, 1993). Such patients
present a therapeutic dilemma. Some surgeons advise immediate
elective lymph node dissection (Balch, 1988; Cochran, 1988) in all
patients with high-risk malignant melanoma (Breslow > 1.5 mm).
They claim that the risk of developing regional node disease
increases with increasing thickness of the primary melanoma.
They argue that lymphadenectomy would most apply to the group
with an intermediate-thickness lesion in the range 1.51-4.0 mm,
when the risk of regional node metastases is high at 57% but the
risk ofdistant metastases is low at 15% (Balch, 1980). They accept
that many patients will undergo an unnecessary operation. Others
adopt a 'wait and see' policy (Roses, 1985; Morton, 1991) and
remove lymph nodes ifand when they become clinically palpable.
They argue that routine elective lymphadenectomy would subject
large numbers ofpatients to an operation that carries a definite and
quite considerable morbidity and a small but inevitable mortality,
and that some such patients will ultimately prove to have no
metastatic disease. Neither policy is ideal.
Clearly, therefore, if a technique could be developed that would
allow positive identification ofthe subgroup ofpatients with clini-
cally occult nodal disease, it may well be that such patients would
benefit from elective lymphadenectomy. Lymphatic mapping may
be such a technique. It is based on a technique that uses a blue dye
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regional lymphatic basin. If the melanoma has metastasized,
tumour cells are most likely to be found in the lymph node closest
to the site ofthe primary melanoma. This first or 'sentinel' node is
usually the first node to be stained blue. The technique was first
described by Morton (1992) and Cochran (1988) in patients with
primary malignant melanoma of a limb. The aim of the present
study was to answer the following questions:
1. Is the technique practical?
2. Is the technique sensitive in identifying the sentinel lymph
node?
3. Can skipping ofthe first nodal basin occur?
MATERIALS AND METHODS
Patient details
The procedure of intraoperative lymph mapping using blue dye
was carried out on 35 patients between February 1992 and
September 1994. The patients with limb malignant melanoma
and lesions > 1.5 mm thick were chosen. The series included 25
women and ten men with a mean age at diagnosis of 57 years
(range 25-80). All 35 patients had 'clinically assessed' stage I
disease (primary disease). The primary lesions were situated on the
lower limb in 29 patients and upper limb in six. The mean Breslow
thickness was 3.4 mm (range 1.5-8.1 mm). No patients had
evidence ofdistant metastases at other sites as determined by ultra-
sound, computerized tomography (CT) scan and chestradiography.
Operative technique
The procedure was carried out under general anaesthesia. The dye
used was patent blue V which comes in a prepacked vial
containing 2.5% of patent blue V in a sterile isotonic solution.
Patent blue V can provoke an allergic reaction of varying degrees
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Figure 1 Lymphatic channels stained blue draining to first blue node or
sentinel node
Figure 2 Two lymph nodes staining blue simultaneously, i.e. two sentinel
nodes
of severity. These reactions are rare and can be controlled with
corticosteroid. The dye (0.5-1.0 ml) was injected intradermally
around the site of the primary melanoma using a 25G insulin
syringe.
If the primary melanoma had already been removed, the intra-
dermal injection was made into either side ofthe excision scar. It is
important that injection of the dye is intradermal as subcutaneous
injection will result in passage ofthe dye into the deeper lymphatic
channels along the veins, bypassing the nodes that drain the
dermal plexus.
The injection site was gently massaged to encourage passage of
the dye along the lymphatics. When the injection was complete, an
incision was made over the lymph basin that is the site of the
expected lymphatic drainage. The skin flap closest to the primary
melanoma was then dissected free from the underlying tissue and
lymphatic channels, taking care to remain superficial to the
lymphatic channels. When a blue lymphatic channel was identi-
fied, it was followed through the fatty subcutaneous tissue to the
first blue-stained lymph node, i.e. the sentinel node (Figure 1). In
some patients there can be more than one sentinel node (Figure 2).
Careful exploration was carried out around the sentinel node to
identify any additional blue nodes. When the sentinel node had
been identified, it was carefully removed with control of all
surrounding lymphatic channels. In patients with lower limb
isolated limb perfusion (ILP), lymph nodes from the iliac region,
i.e. the second lymph node basin, were invariably removed while
dissecting the external iliac vessels. Thus, all patients undergoing
lower limb ILP had some nodes removed from the inguinal and
iliac nodal basin as a result ofdissection to perform ILP, whereas in
axillary ILP some axillary nodes were also removed, in addition to
the sentinel node. All the patients in this study underwent adjuvant
isolated limb perfusion with melphalan for the treatment of their
primary melanoma following their sentinel node biopsy. Radical
lymphadenectomy was performed as a separate procedure only if
the sentinel node was positive. It is not the policy to perform elec-
tive lymph node dissection, and thus the patients with negative
sentinel nodes did not undergo lymphadenectomy (Scott, 1993).
RESULTS
Operative and post-operative complications
There were no complications associated with the use ofpatent blue
V dye in this study. However, some minutes after the injection of
the dye, the skin of the patient becomes blue. This affects the
monitoring of transcutaneous oxygen levels using pulse oximetry
so the anaesthetist must be warned about the dye being used.
All patients reported the presence of dye in their urine during
the first 24 h after the procedure. No hypersensitivity reactions
were recorded.
Sentinel node analysis
In the 35 patients, 37 sentinel nodes were identified: 33 singles and
two doubles. There were nine positive sentinel nodes, of which
eight were from the inguinal basin and one from the axillary basin.
Six of these metastases were detected by both routine H&E and
immunohistochemical staining. In three, metastatic tumour cells
were detected only in sections stained by immunohistochemical
techniques.
Twenty-six patients had no evidence of metastatic disease in the
sentinel node. Nine of the 35 patients (26%) had evidence of
micrometastatic disease; seven of nine (78%) had sentinel node as
the only site of disease. Table 1 shows the metastatic distribution
of these nine patients.
In relation to the Breslow thickness of the primary malignant
melanoma, there were two out of nine positive sentinel nodes in
the group with primary melanoma 1.5-2.99 mm thick and 7 out of
26 positive sentinel nodes in the group with melanoma greater
than 3.00 mm thick.
Ofthe nine patients with positive sentinel nodes, seven had ulcer-
ation in the primary tumour. In the 26 patients with negative sentinel
nodes, only one had ulceration in the primary lesion. This was in a
patient with a subungual melanoma of the right thumb (8.0 mm
thick) and in whom the sentinel node was negative but one lymph
node removed from the iliac region was positive. This patient is
currently disease free with no recurrence. There were no identifying
features to explain this finding. The patient did not undergo radical
lymphadenectomy as her sentinel node was negative.
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Table 1 Distribution of nodal metastases in patients with positive sentinel
node













At a mean follow-up of 20 (range 10-40) months, 31 patients with
negative sentinel nodes have had no local or lymph node recur-
rence ofmelanoma or distant metastases. In nine patients in whom
micrometastases were identified, three have since developed local
recurrence and distant metastases, one of these patients having
now died.
DISCUSSION
To date, the surgical world has had considerable difficulty in
knowing how to deal with lymph nodes that may or may not
contain metastatic malignancy. Most would agree that involved
lymph nodes should be removed, but what if nodes are not clini-
cally known to be involved and yet contain micrometastases? Such
a situation is probably more common than hitherto realized and
has important implications for the staging of disease and interpre-
tation oftherapeutic trials.
In 1992, Morton (1992) and Cochran (1992) at the John Wayne
Institute for Cancer Treatment at UCLA School of Medicine, Los
Angeles, described the technique of lymphatic mapping. They
detected micrometastases in 18% of sentinel nodes removed from
patients with high-risk (1.5-4.0 mm) stage I malignant melanoma.
Ofthe non-sentinel nodes removed from the nodal basin, none was
found to contain micrometastases, suggesting that the tumour status
ofthe sentinel node is reliably predictive ofoverall node status.
Before using the blue dye technique, Morton and many others
were advocates ofelective lymph node dissection (ELND) in limb
malignant melanoma, but intraoperative lymph mapping may
provide an alternative method of management, allowing lympha-
denectomy to be reserved for patients in whom metastases are
positively identified.
Our experience confirms that this technique is easy to master.
We have not encountered allergic reactions to the dye, but it is
important to warn the anaesthetist that the dye affects transcuta-
neous oxygen monitoring as the skin of the patient becomes blue.
It is also important to warn patients that it is usual to have staining
at the site of injection, that their skin may have a generalized blue
tinge and that for 24-48 h their urine will be blue. These reactions
are temporary and resolve spontaneously. At the International
Symposium on Lymphology (Zurich 1966) general reports of
adverse reactions to blue dyes used were given and a probable
incidence of hypersensitivity reactions of 1:1000 concluded. The
hypersensitivity reactions ranged from hives to angioneurotic
oedema, with or without laryngospasm to vasomotor collapse
(Koehler, 1966).
In this study both routine H&E and immunohistochemical
staining were used to assess the sentinel lymph node. The three
immunohistochemical stains used were S-100 protein antibody,
NKIC3 antibody and HMB45 antibody. In lymph nodes that were
positive for micrometastases by immunohistochemical staining,
deeper section H&E-stained nodes failed to detect micrometas-
tases. The results in this study show that routine staining with
H&E alone is not sensitive and specific enough to detect all
micrometastases in lymph nodes. The size of the nodes did not
predict lymph node involvement. Cochran (1982) in a recent study
showed that the number of lymph nodes demonstrating melanoma
cells is significantly higher when S-100 protein antibody label is
used in comparison with conventional H&E-stained sections. It is
therefore important to combine routine H&E staining with S-100
NKIC3 and HMB45 antibodies.
Although it is possible to carry out frozen section analysis ofthe
sentinel node and proceed to performing a radical lymphadenec-
tomy if necessary at the same operation, few centres have on-site
facilities to make this reliable and practical. Moreover, betterpatho-
logical identification of tumour cells is obtained with paraffin-
processed tissue, which takes time. If indicated, we carried out
radical lymphadenectomy as a separate procedure at a later date.
Our experience of the blue dye technique allowed detection of
metastases in 26% of sentinel nodes. If this technique is to have
wide application it is critical that the theory ofmetastatic spread is
sound and that lymphatic drainage occurs in an orderly fashion to
the nearest draining node and lymphatic basin. If micrometastases
can skip an entire nodal basin, then the sentinel node theory will
not be widely applicable in clinical practice. Morton (1992) and
Cochrane (1992) did not identify node basin 'skipping' in their
study. Reintgen (1994), in a recent study (42 patients), confirmed
the accuracy of the technique. They used preoperative lympho-
scintigraphy to mark the location of the sentinel node. Those
patients in their study with negative sentinel node on histological
examination showed no evidence of metastatic disease in any of
the higher nodes sampled with the complete node dissection,
confirming the original observation by Morton (1992).
In our study, however, we found in a single patient in whom the
sentinel node in the inguinal basin was negative, by the methods
previously described, a positive node was encountered in the iliac
region. This at least suggests that skipping of the sentinel node
(1/37) and the first nodal basin can occur.
When the prognostic factors in our 35 patients were analysed
with regard to predicting sentinel node status, several points
emerged. Firstly, it showed that there was a higher incidence of
positive sentinel node with increasing Breslow thickness of the
original tumour, i.e. in the group with a thickness of 1.5-2.99 mm
there were two out ofnine (22%) cases with positive sentinel node
compared with 7 out of 26 (26%) in the group with thickness
above 3.0 mm. This is perhaps not surprising as the proponents of
elective lymphadenectomy claim that the risk of developing
regional node disease increases with the thickness of the primary
melanoma and propose that elective lymph node dissection is
beneficial in those patients with intermediate thickness tumour
(1.5-4.0 mm) (Das Gupta, 1977; Day, 1982).
Secondly, ulceration did appear to be significant in the predic-
tion ofsentinel node status. Seven ofthe nine patients with positive
sentinel nodes had ulceration in the primary tumour, whereas only
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1 of the 26 patients with negative sentinel nodes had ulceration in
the primary tumour. This confirms what has been known for many
years: that ulceration is a prognostic factor (Balch, 1980).
This study has shown that 26% ofpatients with no evidence of
nodal involvement as determined by clinical and radiological
methods in facthave microscopic metastases in the regional lymph
nodes. In all the current staging systems, the presence ofinvolved
nodes reflects more advanced disease. If sentinel node status is
taken into account in these patients, their true staging would be
stage IIIB according to the MD Anderson Staging System.
Clearly, current staging techniques such as CT scanning and
ultrasound are not sufficiently sensitive in identifying nodal
involvement. Intraoperative lymphatic mapping is a tool that the
surgeon can use not only to identify patients who may benefit from
lymphadenectomy, but also to obtain a more accurate staging of
the disease. A more recent modification ofthe blue node mapping
technique involves the use of a portable hand-held radioisotope
detection system, the so-called Neoprobe (van der Veen, 1994).
Using this instrument, not only can the sentinel node be assessed
for the presence of isotope activity after removal, but the nodal
basin can also be scanned to ensure that no residual isotope
activity remains. The ability to identify the sentinel node is related
to a learning curve. With time, this technique becomes easy to
master. We have had no difficulties in identifying the sentinel node
and continue our practice of identification of the sentinel node
without the aid oflymphoscintinography. We would, however, like
to bring to the readers' attention the fact that lymphoscintigraphy
has been used by other investigators to aid in the identification of
the sentinel node.
As shown here and in other studies (Cochran 1982; Cochran
1992; Morton 1992; van der Veen, 1994), the sentinel node does
reflect the histology ofthe lymph node basin accurately. By using
the sentinel node as aprognostic factor, more conservative surgery
can be performed, with radical lymphadenectomy reserved for
those with a positive sentinel node.
If 25% of patients with clinically stage I disease have nodal
involvement, then this also has important implications in the
design and interpretation of therapeutic trials, as a significant
number ofpatients will be understaged.
In conclusion, we have found that lymphatic mapping is a
simple andeasy technique to master. Although we have shown that
skipping of nodal basin can occur, this technique still reliably
identifies the sentinel node and can be used to select patients who
may benefit from elective lymph node dissection.
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